This inventor holds 2 USPTO granted patents. Top assignee: Academia Sinica. Active years: 2013-2014.
Location History:
- Taipei, CN (2013)
- Taipei, TW (2014)
Company Filing History:
Years Active: 2013-2014
Title: Tsewen Chang: Innovator in Antibody Development
Introduction
Tsewen Chang is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of immunology through his innovative work on antibodies. With a total of 2 patents, Chang is recognized for his advancements in targeting B lymphocytes for therapeutic purposes.
Latest Patents
Chang's latest patents focus on the development of Anti-CεmX antibodies capable of binding to human mIgE on B lymphocytes. This invention pertains to the generation and utility of antibodies that can effectively bind to the CεmX domain on membrane-bound IgE (mIgE) expressed on the surface of human B lymphocytes. The CεmX domain consists of 52 amino acid residues and is located between the CH4 domain and the C-terminal membrane-anchor peptide on the human membrane-bound epsilon chain. It has been suggested as an antigenic site for immunological targeting of B cells expressing mIgE. Previous monoclonal antibodies, including a20, which bind to the RADWPGPP peptide at the C-terminal of CεmX, have been found to bind poorly to mIgE on human B cells. Chang's research has led to the discovery that only monoclonal antibodies specific for certain segments, such as GLAGGSAQSQRAPDRVL and HSGQQQGLPRAAGGSVPHPR, can bind effectively to mIgE on human B cells. This finding has significant implications for targeting those B cells in the treatment of diseases mediated by IgE.
Career Highlights
Tsewen Chang is affiliated with Academia Sinica, a prestigious research institution in Taiwan. His work has garnered attention for its potential impact on immunological therapies and treatments.
Collaborations
Chang has collaborated with notable colleagues, including Alfur F Hung and Pheidias C Wu, to advance his research in antibody development.
Conclusion
Tsewen Chang's innovative work in the field of immunology, particularly in the development of antibodies targeting B lymphocytes, showcases his significant contributions to medical science. His patents reflect a commitment to advancing therapeutic options for diseases mediated by IgE.